Avalyn Pharma Inc. Increase (Decrease) in Prepaid Expense and Other Assets
Avalyn Pharma Inc. (AVLN) reported Increase (Decrease) in Prepaid Expense and Other Assets of $192.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets · last filed 2026-08-12
- Avalyn Pharma Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-06-30 was -$316.00K, a 213.26% decline year-over-year.
- Avalyn Pharma Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-03-31 was $508.00K, a 91.70% increase year-over-year.
- Avalyn Pharma Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-06-30 was $279.00K.
- Avalyn Pharma Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-03-31 was $265.00K.
| Period end | Increase (Decrease) in Prepaid Expense and Other Assets 3 month | Increase (Decrease) in Prepaid Expense and Other Assets 6 month |
|---|---|---|
| 2026-06-30 | -$316.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $192.00K 10-Q · filed 2026-08-12 |
| 2026-03-31 | $508.00K 10-Q · filed 2026-06-03 | |
| 2025-06-30 | $279.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $544.00K 10-Q · filed 2026-08-12 |
| 2025-03-31 | $265.00K 10-Q · filed 2026-06-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B |